Educating healthcare professionals and researchers about drug-induced and iatrogenic respiratory diseases (DIRD) fosters a better understanding of the underlying mechanisms, risk factors, and potential management strategies. It helps them to understand the relationship between drugs and lung health, the risks associated with drug use and how to prevent drug-related lung diseases.
The Drugs and lungs – liaisons dangereuses webinar series is a seven-part programme that will take place from 26 June 2023 to 29 April 2024.
Educational aims
This webinar series aim to help participants develop a better understanding of the relationship between drugs and lungs. This knowledge can help them identify the signs and symptoms of drug-induced lung diseases (DILD) and provide appropriate care to patients.
Topics
- DILD Toolbox and essentials to start with
- DILD in interstitial lung diseases
- DILD in cancer treatment
- Drug-associated pulmonary arterial hypertension (PAH)
- DILD and systemic diseases
Learning outcomes
Following these seven webinars, participants will be able to:
- Recognise the impact of drug-induced diseases on lung health.
- Identify the different types of drugs that can cause lung disease.
- Understand the mechanisms by which drugs affect lung health and the impact of drug use on lung function.
- Recognise the signs and symptoms of respiratory problems related to medications.
- Optimise treatment by choosing alternative medications that are less likely to cause respiratory side effects.
Format and schedule
Each of the seven webinars will cover different aspects of drug-induced or iatrogenic respiratory diseases.
- Session one: Drug-induced lung diseases (DILD) – Toolbox and essentials to start with
- Session two: Interstitial lung diseases – Inflammation, fibrosis and oedema
- Session three: Interstitial lung diseases – Drugs and chemicals
- Session four: DILD in cancer treatment
- Session five: Drug-associated pulmonary arterial hypertension (PAH)
- Session six: DILD and systemic diseases
- Session seven: Respiratory injury from illicit drugs and substances
Check the Programme tab for more details regarding each session.
CME credits
An application will be submitted to the European Board for Accreditation in Pneumology (EBAP) for CME accreditation of this event. The number of credits that you will receive will correspond to the time you spend viewing the sessions live.
Recordings
Video recordings of each session will be made available to registered participants within two weeks of each session.
Register now
Below you can register for each session individually or benefit from reduced fees by registering for multiple sessions or the full series.
| Full series | Register here |
| Session 1 (26 June, 2023) | Registration closed |
| Session 2 (4 September, 2023) | Registration closed |
| Session 3 (23 October, 2023) | Registration closed |
| Session 4 (27 November, 2023) | Registration closed |
| Session 5 (22 January, 2024) | Registration closed |
| Session 6 (18 March, 2024) | Registration closed |
| Session 7 (29 April, 2024) | Register here |
Session one: Drug-induced lung diseases (DILD) – Toolbox and essentials to start with
26 June, 2023
18:00-19:30 CEST
Chairs: Prof. Philippe Camus (Dijon, France), Prof. Katerina Antoniou (Heraklion, Greece)
Speakers: Prof. Philippe Camus (Dijon, France), Dr Sara Piciucchi (Forlì, Italy), Prof. Athol Wells (London, United Kingdom)
Topics:
- Where are we now, after 70 years of literature (including Pneumotox)
Philippe Camus - DILD and DIRD imaging
Sara Piciucchi - How to secure and grade the diagnosis. How patients should be managed
Athol Wells
Registration closed
Session two: Interstitial lung diseases – Inflammation, fibrosis and oedema
4 September, 2023
18:00-19:00 CEST
Chairs: Prof. Elisabetta Renzoni (London, United Kingdom), Prof. David Montani (Le Kremlin-Bicêtre, France)
Speakers: Dr Elisabeth Bendstrup (Aarhus, Denmark), Prof. Philippe Bonniaud (Dijon, France), Prof. Katerina Antoniou (Heraklion, Greece)
Topics:
- Deciphering mild to acute drug-induced lung disease
Elisabeth Bendstrup - The spectrum of drug-induced eosinophilic respiratory disease
Philippe Bonniaud
- Pulmonary fibrosis: causality assessment of drugs
Katerina Antoniou
Registration closed
Session three: Interstitial lung diseases – Drugs and chemicals
23 October, 2023
18:00-19:00 CET
Chairs: Prof. Philippe Camus (Dijon, France), Dr Nazia Chaudhuri (Limavady, United Kingdom)
Speakers: Dr Nicole Ng (New York, United States), Prof. Isabella Annesi Maesano (Montpellier, France), Dr Fabien Maldonado (Brentwood, United States)
Topics:
- Classic drugs causing toxicity: amiodarone, antimicrobial agents, etc
Nicole Ng - Newcomers: MTOR; TMP-SMX, antidepressants, NOACs
Fabien Maldonado - E-cigarette and other inhaled lung injuries
Isabella Annesi Maesano
Registration closed
Session four: DILD in cancer treatment
27 November, 2023
18:00-19:00 CET
Chairs: Prof. Elisabetta Renzoni (London, United Kingdom), Prof. Luca Richeldi (Roma, Italy)
Speakers: Dr Jennifer Possick (New Haven, United States), Dr Louise Bondeelle (Geneva, Switzerland), Dr Georgia Hardavella (Athens, Greece)
Topics:
- DIRD in the treatment of solid tumours (focus on immune checkpoint inhibitors)
Jennifer Possick - DIRD in liquid or hematologic malignancies (incl bleomycin)
Louise Bondeelle - The multifaceted injury from radiation therapy to the chest
Georgia Hardavella
Registration closed
Session five: Drug-associated pulmonary vascular disorders
22 January, 2024
18:00-19:00 CET
Chairs: Prof. David Montani (Le Kremlin-Bicêtre, France), Prof. Katerina Antoniou (Heraklion, Greece)
Speakers: Dr Charles Khouri (Grenoble, Auvergne-Rhône-Alpes, France), Prof. David Montani (Le Kremlin-Bicêtre, France), Dr Vinicio De Jesus Perez (Palo Alto, United States)
Topics:
- Using pulmonary arterial hypertension to demonstrate capturing pharmacovigilance signals in rare iatrogenic diseases
Charles Khouri - PAH and PVOD induced by anti-neoplastic (cancer) drugs
David Montani - Breaking bad: exploring the association between methamphetamine and other substance abuse and pulmonary arterial hypertension
Vinicio de Jesus Perez
Registration closed
Session six: DILD and systemic diseases
18 March, 2024
18:00-19:00 CET
Chairs: Prof. Philippe Camus (Dijon, France), Dr Maria Molina Molina (Barcelona, Spain)
Speakers: Dr Pilar Rivera Ortega (Manchester, United Kingdom), Dr Puja Mehta (London, United Kingdom), Dr Pierre-Antoine Juge (Paris, France)
Topics:
- Drug-induced systemic conditions
Pilar Rivera Ortega - Drug-induced respiratory disease in systemic and connective tissue disease
Puja Mehta - Methotrexate and the lung
Pierre-Antoine Juge
Registration closed
Session seven: Respiratory injury from illicit drugs and substances
29 April, 2024
18:00-19:00 CEST
Chairs: Dr Stamatoula Tsikrika (Athens, Greece), Dr Claudia Ravaglia (Forlì, Italy)
Speakers: Dr Jacobo Sellares Torres (Barcelona, Spain), Dr Andreas M. Matthaiou (Athens, Greece), Dr Bruno Megarbane (Paris, France)
Topics:
- The opioid and stimulant epidemics: epidemiology, recognition, management, and prevention
Jacobo Sellares Torres - Why are stimulant-induced overdose deaths increasing? Why are racial and ethnic minority populations more affected than others?
Andreas M. Matthaiou - The crisis of opioid overdose fatalities: What’s new in 2024?
Bruno Megarbane
Register now: session 7
Register now: full series
|
|
Single session | More than 1 session* | ||
| Member | Non-member | Member |
Non-member |
|
|
Full series |
€100 | €160 | – | – |
|
Session 1 |
€25 | €40 | €15 |
€24 |
|
Session 2 |
€25 | €40 | €15 |
€24 |
|
Session 3 |
€25 | €40 | €15 |
€24 |
|
Session 4 |
€25 | €40 | €15 |
€24 |
|
Session 5 |
€25 | €40 | €15 |
€24 |
|
Session 6 |
€25 | €40 | €15 |
€24 |
| Session 7 | €25 | €40 | €15 |
€24 |
*Registering for multiple sessions: a discount will be applied automatically after the first registration.
Cancellation policy
Registration fees are non-refundable.
Terms and conditions
Registering for someone else? Contact registration@ersnet.org
Diseases/methods:
- Interstitial lung diseases
- Pulmonary vascular diseases
- Thoracic oncology
Target audience
- Clinicians
- Trainees
- Scientists
- Pulmonologists
- Research fellows
- Allied respiratory professionals